Skip to main content

Advertisement

SpringerLink
Log in

Treatment Response and Outcome with Two Different Prednisolone Regimens in Autoimmune Hepatitis

  • Original Article
  • Published:
Digestive Diseases and Sciences Aims and scope Submit manuscript

Abstract

Background

Beyond available guidelines, therapy of autoimmune hepatitis (AIH) shows wide variation among physicians. We compared two regimens for treatment naive AIH: one recommended protocol with an initial prednisolone dose of 30 mg/day and our own 40 mg/day prednisolone with a slow dose tapering protocol. We analyzed the safety, response rates, and outcomes for two groups of treated patients.

Patients and Methods

We retrospectively evaluated data of 71 AIH patients including, group I (n = 32, prednisone 30 mg/day) and group II (n = 39, prednisone 40 mg/day). All patients also received azathioprine.

Results

The frequency of complete biochemical response was significantly higher in group II than in group I (69.2 vs. 43.8%, p = 0.031) after 3 months of therapy, but not after 6 and 12 months (79.5 vs. 59.4%, p = 0.065 and 89.5 vs. 80.6%, p = 0.30). In patients with severe interface hepatitis, the complete response rates were significantly higher in group II than in group I after 3 (63.6 vs. 23.1%, p = 0.02) and 6 months (72.7 vs. 38.5%, p = 0.046), but not after 12 months of therapy (86.4 vs. 69.2%, p = 0.221). Relapses were observed in 50% of group I and in 35.9% of group II during maintenance therapy (p = 0.23). Overall survival was significantly better in group II than in group I (100 vs. 87.5%, log-rank, p = 0.048). No severe steroid-related side effects were observed in either group.

Conclusions

Our real-world experience suggests that an initial prednisolone dose of 40 mg/day with a slower tapering protocol induces earlier biochemical response, tends to result in less relapses during maintenance, and is associated with a better disease outcome.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Efe C, Ozaslan E, Wahlin S, et al. Antibodies to soluble liver antigen in patients with various liver diseases: a multicentre study. Liver Int. 2013;33:190–196.

    Article  CAS  PubMed  Google Scholar 

  2. Manns MP, Czaja AJ, Gorham JD, et al. Diagnosis and management of autoimmune hepatitis. Hepatology. 2010;51:2193–2213.

    Article  CAS  PubMed  Google Scholar 

  3. Soloway RD, Summerskill WH, Baggenstoss AH, et al. Clinical, biochemical, and histological remission of severe chronic active liver disease: a controlled study of treatments and early prognosis. Gastroenterology. 1972;63:820–833.

    CAS  PubMed  Google Scholar 

  4. Murray-Lyon IM, Stern RB, Williams R. Controlled trial of prednisone and azathioprine in active chronic hepatitis. Lancet. 1973;1:735–737.

    Article  CAS  PubMed  Google Scholar 

  5. Lamers MM, van Oijen MG, Pronk M, Drenth JP. Treatment options for autoimmune hepatitis: a systematic review of randomized controlled trials. J Hepatol.. 2010;53:191–198.

    Article  CAS  PubMed  Google Scholar 

  6. European Association for the Study of the Liver. EASL clinical practice guidelines: autoimmune hepatitis. J Hepatol. 2015;63:971–1004.

    Article  Google Scholar 

  7. Czaja AJ. Rapidity of treatment response and outcome in type 1 autoimmune hepatitis. J Hepatol. 2009;51:161–167.

    Article  CAS  PubMed  Google Scholar 

  8. Kanzler S, Löhr H, Gerken G, Galle PR, Lohse AW. Long-term management and prognosis of autoimmune hepatitis (AIH): a single center experience. Z Gastroenterol. 2001;39:344–348.

    Article  Google Scholar 

  9. Czaja AJ. Global disparities and their implications in the occurrence and outcome of autoimmune hepatitis. Dig Dis Sci. 2017; doi:10.1007/s10620-017-4675-y.

    PubMed  Google Scholar 

  10. Gleeson D, Heneghan MA. British society of gastroenterology (BSG) guidelines for management of autoimmune hepatitis. Gut. 2011;60:1611–1629.

    Article  CAS  PubMed  Google Scholar 

  11. Liberal R, de Boer YS, Andrade RJ, et al. Expert clinical management of autoimmune hepatitis in the real world. Aliment Pharmacol Ther. 2017;45:723–732.

    Article  CAS  PubMed  Google Scholar 

  12. Hennes EM, Zeniya M, Czaja AJ, et al. Simplified criteria for the diagnosis of autoimmune hepatitis. Hepatology. 2008;48:169–176.

    Article  PubMed  Google Scholar 

  13. Vierling JM. Autoimmune hepatitis and overlap syndromes: diagnosis and management. Clin Gastroenterol Hepatol. 2015;13:2088–2108.

    Article  PubMed  Google Scholar 

  14. Stravitz TR, Lefkowitch J, Fontana R, et al. Autoimmune acute liver failure: proposed clinical and histological criteria. Hepatology. 2011;53:517–526.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology. 1996;24:289–293.

    Article  CAS  PubMed  Google Scholar 

  16. Manns MP, Woynarowski M, Kreisel W, et al. Budesonide induces remission more effectively than prednisone in a controlled trial of patients with autoimmune hepatitis. Gastroenterology. 2010;139:1198–1206.

    Article  CAS  PubMed  Google Scholar 

  17. Zachou K, Gatselis N, Papadamou G, Rigopoulou EI, Dalekos GN. Mycophenolate for the treatment of autoimmune hepatitis: prospective assessment of its efficacy and safety for induction and maintenance of remission in a large cohort of treatment-naïve patients. J Hepatol. 2011;55:636–646.

    Article  CAS  PubMed  Google Scholar 

  18. Van Thiel DH, Wright H, Carroll P, et al. Tacrolimus: a potential new treatment for autoimmune chronic active hepatitis: results of an open-label preliminary trial. Am J Gastroenterol. 1995;90:771–776.

    PubMed  PubMed Central  Google Scholar 

  19. Montano-Loza AJ, Thandassery RB, Czaja AJ. Targeting hepatic fibrosis in autoimmune hepatitis. Dig Dis Sci. 2016;61:3118–3139.

    Article  CAS  PubMed  Google Scholar 

  20. Hoeroldt B, McFarlane E, Dube A, et al. Long-term outcomes of patients with autoimmune hepatitis managed at a non-transplant center. Gastroenterology. 2011;140:1980–1989.

    Article  PubMed  Google Scholar 

  21. Dhaliwal HK, Hoeroldt BS, Dube AK, et al. Long-term prognostic significance of persisting histological activity despite biochemical remission in autoimmune hepatitis. Am J Gastroenterol. 2015;110:993–999.

    Article  CAS  PubMed  Google Scholar 

  22. Czaja AJ. Late relapse of type 1 autoimmune hepatitis after corticosteroid withdrawal. Dig Dis Sci. 2010;55:1761–1769.

    Article  CAS  PubMed  Google Scholar 

  23. Van Gerven NM, Verwer BJ, Witte BI, et al. Relapse is almost universal after withdrawal of immunosuppressive medication in patients with autoimmune hepatitis in remission. J Hepatol. 2013;58:141–147.

    Article  PubMed  Google Scholar 

  24. Czaja AJ. Advances in the current treatment of autoimmune hepatitis. Dig Dis Sci. 2012;57:1996–2010.

    Article  CAS  PubMed  Google Scholar 

  25. Efe C, Hagström H, Ytting H, et al. Efficacy and safety of mycophenolate mofetil and tacrolimus as second-line therapy for patients with autoimmune hepatitis. Clin Gastroenterol Hepatol. 2017. doi:10.1016/j.cgh.2017.06.00.

    Google Scholar 

  26. Choy E. Understanding the dynamics: pathways involved in the pathogenesis of rheumatoid arthritis. Rheumatology (Oxford). 2012;51:v3–v11.

    Article  CAS  Google Scholar 

  27. Montano-Loza AJ, Czaja AJ. Cell mediators of autoimmune hepatitis and their therapeutic implications. Dig Dis Sci.. 2015;60:1528–1542.

    Article  CAS  PubMed  Google Scholar 

  28. Handzlik-Orlik G, Holecki M, Wilczyński K, Duława J. Osteoporosis in liver disease: pathogenesis and management. Ther Adv Endocrinol Metab. 2016;7:128–135.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Yeoman AD, Westbrook RH, Zen Y, et al. Early predictors of corticosteroid treatment failure in icteric presentations of autoimmune hepatitis. Hepatology. 2011;53:926–934.

    Article  PubMed  Google Scholar 

  30. Al-Chalabi T, Underhill JA, Portmann BC, McFarlane IG, Heneghan MA. Effects of serum aspartate aminotransferase levels in patients with autoimmune hepatitis influence disease course and outcome. Clin Gastroenterol Hepatol. 2008;6:1389–1395.

    Article  PubMed  Google Scholar 

  31. Ngu JH, Gearry RB, Frampton CM, Stedman CA. Predictors of poor outcome in patients with autoimmune hepatitis: a population-based study. Hepatology. 2013;57:2399–2406.

    Article  CAS  PubMed  Google Scholar 

Download references

Author’s contribution

TP and CE contributed equally. TP, CE, and EO conceptualized the study. TP and CE collected and analyzed data, wrote the manuscript. TP, CE, EO, TK, and SW interpreted data and prepared manuscript for the final submission.

Author information

Authors and Affiliations

  1. Department of Gastroenterology, Hacettepe University, Ankara, Turkey

    Tugrul Purnak, Cumali Efe & Taylan Kav

  2. Hepatology Division, Centre for Digestive Disease, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden

    Staffan Wahlin

  3. Department of Gastroenterology, Numune Research and Education Hospital, Ankara, Turkey

    Ersan Ozaslan

Authors
  1. Tugrul Purnak
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Cumali Efe
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Taylan Kav
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Staffan Wahlin
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Ersan Ozaslan
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Cumali Efe.

Ethics declarations

Conflict of interest

None.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Purnak, T., Efe, C., Kav, T. et al. Treatment Response and Outcome with Two Different Prednisolone Regimens in Autoimmune Hepatitis. Dig Dis Sci 62, 2900–2907 (2017). https://doi.org/10.1007/s10620-017-4728-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10620-017-4728-2

Keywords

Search

Navigation